Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

被引：388

作者：

Reynolds, Andrew R. ^{[1
,3
]}

Hart, Ian R. ^{[2
]}

Watson, Alan R. ^{[1
]}

Welti, Jonathan C. ^{[3
]}

Silva, Rita G. ^{[1
]}

Robinson, Stephen D. ^{[1
]}

Da Violante, Georges ^{[4
]}

Gourlaouen, Morgane ^{[3
]}

Salih, Mishal ^{[1
]}

Jones, Matt C. ^{[5
]}

Jones, Dylan T. ^{[1
]}

Saunders, Garry ^{[6
]}

Kostourou, Vassiliki ^{[1
]}

Perron-Sierra, Francoise

Norman, Jim C. ^{[5
]}

Tucker, Gordon C. ^{[7
]}

Hodivala-Dilke, Kairbaan M. ^{[1
]}

机构：

[1] Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Canc,John Vane Sci Ctr, Adhes & Angiogenesis Lab, London, England

[2] Queen Mary Univ London, Barts & London Sch Med & Dent, Inst Canc,John Vane Sci Ctr, Tumor Biol Ctr, London, England

[3] Inst Canc Res, Breakthrough Breast Canc Res Ctr, Tumour Angiogenesis Grp, London SW3 6JB, England

[4] Technol Servier, Orleans, France

[5] Beatson Inst Canc Res, Integrin Cell Biol Lab, Glasgow G61 1BD, Lanark, Scotland

[6] Canc Res UK London Res Inst, Clare Hall Labs, S Mimms, Herts, England

[7] Inst Rech Servier, Canc Res & Drug Discovery Div, Croissy Sur Seine, France

来源：

NATURE MEDICINE | 2009年 / 15卷 / 04期

关键词：

ADVANCED SOLID TUMORS; ENDOTHELIAL-CELLS; IN-VIVO; PATHOLOGICAL ANGIOGENESIS; ALPHA-V-BETA-3; INTEGRIN; CILENGITIDE EMD-121974; MALIGNANT GLIOMA; BREAST-CANCER; PHASE-I; ALPHA;

D O I：

10.1038/nm.1941

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Inhibitors of alpha(v)beta(3) and alpha(v)beta(5) integrin have entered clinical trials as antiangiogenic agents for cancer treatment but generally have been unsuccessful. Here we present in vivo evidence that low (nanomolar) concentrations of RGD-mimetic alpha(v)beta(3) and alpha(v)beta(5) inhibitors can paradoxically stimulate tumor growth and tumor angiogenesis. We show that low concentrations of these inhibitors promote VEGF-mediated angiogenesis by altering alpha(v)beta(3) integrin and vascular endothelial growth factor receptor-2 trafficking, thereby promoting endothelial cell migration to VEGF. The proangiogenic effects of low concentrations of RGD-mimetic integrin inhibitors could compromise their efficacy as anticancer agents and have major implications for the use of RGD-mimetic compounds in humans.

引用

页码：392 / 400

页数：9

共 54 条

[11] In vivo near-infrared fluorescence imaging of integrin a,αvβ3 in brain tumor xenografts
Chen, XY
Conti, PS
Moats, RA
[J]. CANCER RESEARCH, 2004, 64 (21) : 8009 - 8014
[12] The fibronectin-binding integrins α5β1 and αvβ3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis
Danen, EHJ
Sonneveld, P
Brakebusch, C
Fässler, R
Sonnenberg, A
[J]. JOURNAL OF CELL BIOLOGY, 2002, 159 (06) : 1071 - 1086
[13] N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists
Dechantsreiter, MA
Planker, E
Mathä, B
Lohof, E
Hölzemann, G
Jonczyk, A
Goodman, SL
Kessler, H
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) : 3033 - 3040
[14] Manganese-induced integrin affinity maturation promotes recruitment of αVβ3 integrin to focal adhesions in endothelial cells:: evidence for a role of phosphatidylinositol 3-kinase and Src
Dormond, O
Ponsonnet, L
Hasmim, M
Foletti, A
Rüegg, C
[J]. THROMBOSIS AND HAEMOSTASIS, 2004, 92 (01) : 151 - 161
[15] Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination -: Consequences on nitric oxide production from endothelial cells
Duval, M
Bédard-Goulet, S
Delisle, C
Gratton, JP
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (22) : 20091 - 20097
[16] VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, Lee M.
Hicklin, Daniel J.
[J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 579 - 591
[17] Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
Eskens, FALM
Dumez, H
Hoekstra, R
Perschl, A
Brindley, C
Böttcher, S
Wynendaele, W
Drevs, J
Verweij, J
van Oosterom, AT
[J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (07) : 917 - 926
[18] Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells
Ewan, Lorna C.
Jopling, Helen M.
Jia, Haiyan
Mittar, Shweta
Bagherzadeh, Azadeh
Howell, Gareth J.
Walker, John H.
Zachary, Ian C.
Ponnambalam, Sreenivasan
[J]. TRAFFIC, 2006, 7 (09) : 1270 - 1282
[19] Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis
Fan, GH
Lapierre, LA
Goldenring, JR
Sai, JQ
Richmond, A
[J]. MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (05) : 2456 - 2469
[20] Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N
Hillan, KJ
Gerber, HP
Novotny, W
[J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) : 391 - 400

← 1 2 3 4 5 6 →